CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Prolotherapyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03515720
NCT03515720N/ACompleted

Effectiveness of Neuroprolotherapy With Home Physical Therapy Against Isolated Physical Therapy for the Treatment of Patellar Chondromalacia

Instituto Mexicano del Seguro Social·interventional·Posted May 3, 2018·Updated Oct 3, 2023

In Brief

A clinical study evaluating Prolotherapy for Chondromalacia Patellae. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Patellar chondromalacia is the degeneration of articular cartilage located on the posterior face of the patella and may suggest the onset of an osteoarthrosis. It predominates in sedentary people who overload the joint, as well as people with insufficiency in the extensor muscles of the knee. It is often seen between 30 and 40 years. Conservative management is the main treatment option and surgical intervention is considered as a last option in a small number of patients. A new treatment option is neuroprolotherapy where the approach is directed at the subcutaneous nerves as the source of pathology, which can lead to neurogenic inflammation and pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 3, 2018
Enrollment StartNov 1, 2018
Primary CompletionSep 20, 2019
Study CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.2 years ago

Interventions

Prolotherapyprocedure

It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.